Liver

Rheumatic Disease eJournal Club

Certolizumab Pegol Plus Methotrexate
Is Significantly More Effective Than
Placebo Plus Methotrexate in Active Rheumatoid Arthritis: Findings of a Fifty-Two–Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Publication: Keystone E, et al. Arthritis Rheum. 2008;58:3319-3329.

Print this Content

 

Release Date: January 27, 2009
Renewal Date: February 5, 2010
Expiration Date: February 5, 2011

 

 

How to Obtain AMA PRA
Category 1 Credit™

  1. Read the provided journal article and slides.
  2. Listen to the
    audio discussion.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized
    CME certificate.

Technical Requirements

 

Estimated Time of Completion: 45 minutes

Description
To review the efficacy and safety data from a randomized, double-blind, placebo-controlled, parallel-group study of certolizumab in combination with methotrexate.

Objectives
On completion of this activity, participants should be able to:

  1. Discuss the effects of certolizumab and methotrexate combination therapy on RA disease activity.
  2. Outline the effects of certolizumab and methotrexate combination therapy on the progression of radiographic damage.
  3. Describe the adverse events reported in participants treated with certolizumab.

Target Audience
This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA.

Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio

Faculty

Edward C. Keystone, MD, FRCP(C)
Professor of Medicine
University of Toronto
Director, The Rebecca Macdonald Centre for Arthritis and Autoimmune Disease
Director, the Division of Advanced Therapeutics in Arthritis
Chairman, Canadian Rheumatology Research Consortium
Consultant in Rheumatology
Mount Sinai Hospital/University Health Network
Toronto, Ontario, Canada

Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories; Elan, Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Edward C. Keystone, MD FRCP(C)
  Consulting, Teaching and Speaking, Independent Contractor: UCB

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME .

CME Disclaimer